Biotechnology Development Operations Venture Capitalist 
Harvard Business Review
MAY 2, 2011
As multinational corporations pursue opportunities in emerging markets, they're bound to stumble if they overlook the developed economies, and vice versa. Without operating in the former, they won't be able to attain economies of scale; sans the latter, they're unlikely to continue developing state-of-the-art technologies.
Harvard Business Review
FEBRUARY 17, 2011
Venture capitalists are increasingly interested in emerging markets, and in working with local funds based in those markets (despite the fact that reverse innovation in venture capital seems counterintuitive). Editor's Note: This post was written with Justin Chakma, an undergraduate student at the University of Toronto (Canada).
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Harvard Business Review
OCTOBER 26, 2011
Many venture capitalists are limiting their investments to the "demand-side" — aimed at reducing energy use — rather than investing in startups trying to change the way we produce energy. Their behavior displays promising parallels to the early days of the biotechnology industry.
Harvard Business Review
JUNE 16, 2016
The Joint Center For Energy Storage Research (JCESR) has a five-year mandate to develop next generation battery technologies. “But here, we can operate within the time frame of the next coffee break.” Firms have also invested additional money to build facilities near the hubs to better integrate their operations with them.
Harvard Business Review
FEBRUARY 3, 2015
By managing the three key properties of networks that either propel you forward or hold you back—breadth, connectivity, and dynamism—you can develop a stronger network and use it as an essential leadership tool. The result was that their ideas were not developed. The good news is that you can change that.
Expert insights. Personalized for you.
14 
Let's personalize your content